{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87"}]}],"title":"Hypertension"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"title":"Abdominal pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"title":"Diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Nausea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Vomiting"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Mucositis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Oral pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"Headache"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Confusion"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Insomnia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Syncope"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Anxiety"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Intracranial hemorrhage"},{"categories":[{"measurements":[{"groupId":"OG000","value":"27"}]}],"title":"Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Weight loss"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Anorexia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Myalgia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Dehydration"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Hypothyroidism"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Increased transaminases"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Increased alkaline phosphatase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Increased gamma-glutamyl transferase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Urinary tract infection"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Right ventricular dysfunction"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Pain in extremity"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Hand-foot syndrome"}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Grade 2 through 4 toxicities considered at least possibly related to treatment. Percentage of participants affected per category. Safety assessments will consist of monitoring and recording all adverse events and serious adverse events, the regular monitoring of hematology and blood chemistry parameters and regular physical examinations. Adverse events will be evaluated continuously throughout the study. Safety and tolerability will be assessed according to the National Institute of Health/National Cancer Institute (NIH/NCI) Common Terminology Criteria for Adverse Events version 4 (CTCAE v4) available at: http://ctep.cancer.gov/protocolDevelopment/electronic\\_applications/ctc.htm.","groups":[{"description":"The investigational drug used in this study is axitinib, and is available as tablets.","id":"OG000","title":"Axitinib Administration"}],"paramType":"NUMBER","populationDescription":"All participants.","reportingStatus":"POSTED","timeFrame":"12 Months","title":"Occurrence of Possibly Related Adverse Events (AEs)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}